Flow Cytometry-Based Tools to Enrich Your Preclinical Immuno-Oncology Research
Flow cytometry provides a highly adaptable and quantitative method for investigating both the cellular distribution and intracellular changes that occur in tumors and peripheral lymphoid organs in response to therapy. As clinical successes with cancer immunotherapy accumulate, preclinical immuno-oncology research depends on greater mechanistic understanding of novel therapeutic strategies. MI Bioresearch offers comprehensive flow panels for immune profiling and functional characterization of immune cell activation state.
Who Should Attend?
- Immuno-oncology/oncology drug discovery scientists
- Assay development scientists
- Flow cytometry core scientists
The objectives of this presentation are three-fold. First, featured speakers will present advanced approaches to ex vivo myeloid and lymphoid immunophenotypic analysis. Emphasis will be placed on the challenges presented by the complex nature of tumor-derived cell analysis. The speakers will describe how these challenges have been overcome to delineate myeloid subsets including myeloid-derived suppressor cell, macrophage, and dendritic cell subsets. Furthermore, the speakers will demonstrate techniques that can help interpret the effects that in vivo therapy has on immunosuppression in T cells. Next, they will demonstrate techniques that analyze cytokine responses in T cells and other lymphoid cells, which have been documented to drive anti-tumor activity within the tumor microenvironment. Using a case study they will illustrate how these applications can help interpret the efficacy of new drugs. Finally, they will present ex vivo data that dissects the therapeutic effects on MAPK and JAK/STAT signaling pathways in both the tumor cells and tumor-infiltrating lymphocytes simultaneously.
In summary, this presentation will describe advances in flow cytometry-based tools and provide an understanding of how these applications can be used to examine your drug’s mechanism of action.
Dylan Daniel, Ph.D.
Director, Scientific Development
Dr. Dylan Daniel, is an immunologist and preclinical oncology pharmacologist with leadership experience in all phases of early R&D for oncology and cancer immunotherapy. Dr. Daniel has a Ph.D. in Microbiology and Immunology and conducted post-doctoral work with Doug Hanahan at UCSF where he worked on immuno-oncology in genetically engineered mouse models. From there, Dr. Daniel worked at Genentech and then Novartis. In both companies, he was focused on oncology pharmacology with small molecule and biologic drug discovery and development. Prior to joining MI Bioresearch, Dr. Daniel was Chief Science Officer and Co-Founder of Patronus Therapeutics, Inc., a small biotechnology start-up developing novel oncology therapeutics.
David Draper, Ph.D.
Associate Director, Scientific Development
Dr. David Draper, Associate Director of Scientific Development, has a background as an immunologist and is the flow cytometry subject matter expert at MI Bioresearch. Dr. Draper holds a Ph.D. in Microbiology from North Carolina State University. His post-doctoral work at Duke University and the National Institutes of Health focused on uncovering the mechanisms of the host pulmonary immune response to bacterial, viral, and allergen challenge using genetically engineered animal models. This body of work provided the foundation of Dr. Draper’s technical expertise in the area of immune cell immunophenotypic and functional characterization. Dr. Draper has also held immunodiagnostic and R&D positions within the Clinical Immunology/Flow Cytometry department at the Carolinas Medical Center and BD Biosciences prior to joining MI Bioresearch in 2015.